Serious drawdown of oil quotesToday, oil is actively declining. A very significant increase in the reserves of “black gold” in the United States caused this drop. Moreover, the fears that Russia will not reduce...

Swiss watch makers are in crisisSwiss watch exports in April crashed at a record pace the drop has totaled 81% compared with the same period last year. Halting production and difficulties with sales caused by...

Germany saves LufthansaAn air carrier Deutsche Lufthansa AG has suffered losses because of the spread of the coronavirus pandemic. It became known that the German government had not left the matter unattended...

Today, investors have had an opportunity to see an unprecedented rise in shares of the American company Gilead Sciences Inc. A biopharmaceutical company has been recently engaged in creation of a cure for coronavirus. It seems that it is their specialists who will be able to be the first to combat the virus. An experimental drug developed by the company is called remdesivir. Clinical trials are being held at the University of Chicago Medical Center. It became known that most of the patients in serious condition, sometimes after taking the medicine had been released from hospital. This is a fairly impressive control group, the total number of which is 125 people.

Gilead Sciences specialists are currently conducting mass drug tests on patients whose condition is assessed as grave and moderate. The company’s goal is to test four thousand patients.

Once the impressive successes of the biopharmaceuticals became known to the public, the stock of Gilead Sciences began to grow. Today, the growth continues; since the beginning of the session, the shares have increased 13%.

The material was prepared with the participation of Katya Wilson,
a leading analyst of the brokerage company UFT Group